Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kancera logo — Kancera is developing a new class of drugs for treatment of...

Kancera

Kancera is developing a new class of drugs for treatment of inflammation and cancer

Founded 2010 Sweden Sweden 8 employees Biotechnology, Health Care

General Information

Company Name Kancera
Founded Year 2010
Location Sweden Sweden
Employees 8
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Kancera. To contact Kancera, visit kancera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kancera compare?

A PDF of Kancera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kancera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kancera

Kancera is a Swedish-based biotechnology company founded in 2010. The company is dedicated to developing a new class of small molecule drugs based on the fractalkine system. Fractalkine, a master regulator controlling immune cells and cancer cells, is key in treating acute excessive inflammation and treatment-resistant cancers. Kancera's lead drug candidate KAND567 is currently in a phase II trial to address its cardiac-protective effect following myocardial infarction. Additionally, Kancera has plans to initiate a phase I/II study of KAND567 in ovarian cancer in 2023. The company's stock is traded on the Nasdaq First North Premier Growth Market. As a biotech startup targeting the critical areas of inflammation and cancer treatment, Kancera showcases promising potential for growth and innovation in the healthcare industry.

Taxonomy: drug development, inflammation treatment, cancer treatment, fractalkine system, small molecule drugs, immune cell regulation, cardiac-protective drugs, phase II trial, ovarian cancer, Nasdaq First North Premier Growth Market, Swedish biotech company

No funding data available for Kancera yet.

Latest News

View All
VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs — Medcitynews.com
VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs
Medcitynews.com Jul 08, 2020

Kancera Alternatives & Competitors

View All Alternatives
Kancera vs
Talus Bio
Talus Bio United States

Gene regulator profiling in live cells for drug development

Grant
24 employees
Biotechnology, Health Care
Kancera vs
Tetralogic Pharmaceuticals
Tetralogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
Kancera vs
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc. Canada

A new target in cancer care - triggering selective lethality with a new class of drugs.

Grant
9 employees
Biotechnology, Health Care
View all alternatives

FAQ About Kancera

Kancera is developing a new class of drugs for treatment of inflammation and cancer
Kancera was founded in 2010.
Kancera is headquartered in Sweden.
Kancera operates in Biotechnology and Health Care. Its work centres on drug development, inflammation treatment, cancer treatment and fractalkine system.
Kancera has approximately 8 employees.
Top alternatives and competitors to Kancera include Talus Bio, Tetralogic Pharmaceuticals, Pacylex Pharmaceuticals, Inc., Tolerx, Inc., Sirtris Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kancera and Talus Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kancera, https://bouncewatch.com/company/kancera, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes